CoChat
Sign Up
Cited by 61Cervical Cancer and HPV ResearchGenital Health and DiseaseHead and Neck Cancer Studies

Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France

Open access
Riethmuller, Didier, Jacquard, Anne-Carole, Lacau St Guily, Jean, Aubin, François, Carcopino, Xavier, Pradat, Pierre, Dahlab, André, Prétet, Jean-Luc·2015·BMC Public Health
DOI 10.1186/s12889-015-1779-1PMC PMC4433025
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Human Papillomavirus (HPV) infection is known to be associated with a number of conditions including cervical, vaginal, vulvar, penile, anal neoplasias and cancers, oropharynx cancers and genitals warts (GW). Two prophylactic vaccines are currently available: a bivalent vaccine designed to prevent HPV type 16 and 18 infection and a quadrivalent vaccine targeting HPV 6, 11, 16, and 18. In France, HPV vaccination is recommended in 11-14 year-old girls with a catch-up for girls aged 15-19. The objective of this study was to assess the potential impact of an HPV 6/11/16/18/31/33/45/52/58 nonavalent vaccine on anogenital and oropharyngeal HPV-related diseases in France. METHODS: HPV genotype distributions from 6 multicentric retrospective studies (EDiTH I to VI) were analyzed including 516 cases of invasive cervical cancers (ICC), 493 high-grade cervical neoplasias (CIN2/3), 397 low-grade squamous intraepithelial lesions (LSIL), 423 GW, 366 anal cancer and 314 oropharyngeal carcinomas. Low and high estimates of HPV vaccine impact were calculated as follows: low estimate: prevalence of HPV 6/11/16/18/31/33/45/52/58 genotypes alone or in association but excluding presence of another HPV type; high estimate: prevalence of HPV 6/11/16/18/31/33/45/52/58 genotypes alone or in association, possibly in presence of another HPV type. RESULTS: Estimates of potential impact varied from 85% (low estimate) to 92% (high estimate) for ICC, 77% to 90% for CIN2/3, 26% to 56% for LSIL, 69% to 90% for GW, 81% to 93% for anal cancer, and 41% to 44% for oropharyngeal carcinomas. Compared to the quadrivalent vaccine, the proportion of additional cases potentially prevented by the nonavalent vaccine was 9.9%-15.3% for ICC, 24.7%-33.3% for CIN2/3, 12.3%-22.7% for LSIL, 2.1%-5.4% for GW, 8.5%-10.4% for anal cancer, and 0.0%-1.6% for oropharyngeal carcinoma. CONCLUSIONS: The nonavalent HPV vaccine showed significant increased potential impact compared to the HPV 6/11/16/18 quadrivalent vaccine for ICC, CIN2/3 and LSIL. Considering a 100% vaccine efficacy and high vaccine coverage, about 90% of ICC, CIN2/3, GW or anal cancer cases could be prevented by a nonavalent HPV vaccine in France.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12889-015-1779-1

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 23

  1. [1]Dayyani F Etzel CJ Liu M Ho CH Lippman SM Tsao AS Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) Head Neck Oncol 2010 2 15 10.1186/1758-3284-2-15 20587061 PMC2908081 · DOI
  2. [2]De Vuyst H Clifford GM Nascimento MC Madeleine MM Franceschi S Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis Int J Cancer 2009 124 7 1626 36 10.1002/ijc.24116 19115209 · DOI
  3. [3]Mehanna H Jones TM Gregoire V Ang KK Oropharyngeal carcinoma related to human papillomavirus BMJ 2010 340 c1439 10.1136/bmj.c1439 20339160 · DOI
  4. [4]Miralles-Guri C Bruni L Cubilla AL Castellsague X Bosch FX de Sanjose S Human papillomavirus prevalence and type distribution in penile carcinoma J Clin Pathol 2009 62 10 870 8 10.1136/jcp.2008.063149 19706632 · DOI
  5. [5]Bhatia N Lynde C Vender R Bourcier M Understanding genital warts: epidemiology, pathogenesis, and burden of disease of human papillomavirus J Cutan Med Surg 2013 17 Suppl 2 S47 54 24388558
  6. [6]Villa LL Costa RL Petta CA Andrade RP Ault KA Giuliano AR Wheeler CM Koutsky LA Malm C Lehtinen M Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial Lancet Oncol 2005 6 5 271 8 10.1016/S1470-2045(05)70101-7 15863374 · DOI
  7. [7]Brown DR Schroeder JM Bryan JT Stoler MH Fife KH Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients J Clin Microbiol 1999 37 10 3316 22 10488198 PMC85555
  8. [8]Potocnik M Kocjan BJ Seme K Poljak M Distribution of human papillomavirus (HPV) genotypes in genital warts from males in Slovenia Acta Dermatovenerol Alp Panonica Adriat 2007 16 3 91 6 17994168
  9. [10]de Sanjose S Quint WG Alemany L Geraets DT Klaustermeier JE Lloveras B Tous S Felix A Bravo LE Shin HR Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol 2010 11 11 1048 56 10.1016/S1470-2045(10)70230-8 20952254 · DOI · Paper page
  10. [11]Li N Franceschi S Howell-Jones R Snijders PJ Clifford GM Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication Int J Cancer 2011 128 4 927 35 10.1002/ijc.25396 20473886 · DOI
  11. [12]HPV vaccine works against nine viral types. Cancer Discov. 2014;4(1):OF2. 24402954
  12. [13]Serrano B Alemany L Tous S Bruni L Clifford GM Weiss T Bosch FX de Sanjose S Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease Infect Agent Cancer 2012 7 1 38 10.1186/1750-9378-7-38 23273245 PMC3554470 · DOI · Paper page
  13. [14]Pretet JL Jacquard AC Carcopino X Charlot JF Bouhour D Kantelip B Soubeyrand B Leocmach Y Mougin C Riethmuller D Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study Int J Cancer 2008 122 2 428 32 10.1002/ijc.23092 17893882 · DOI
  14. [15]Pretet JL Jacquard AC Carcopino X Monnier-Benoit S Averous G Soubeyrand B Leocmach Y Mougin C Riethmuller D Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study Int J Cancer 2008 122 2 424 7 10.1002/ijc.23093 17893883 · DOI
  15. [16]Pretet JL Jacquard AC Saunier M Clavel C Dachez R Gondry J Pradat P Soubeyrand B Leocmach Y Mougin C Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: the EDiTH III study Gynecol Oncol 2008 110 2 179 84 10.1016/j.ygyno.2008.04.012 18514800 · DOI
  16. [17]Aubin F Pretet JL Jacquard AC Saunier M Carcopino X Jaroud F Pradat P Soubeyrand B Leocmach Y Mougin C Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV) Clin Infect Dis 2008 47 5 610 5 10.1086/590560 18637758 · DOI
  17. [18]Abramowitz L Jacquard AC Jaroud F Haesebaert J Siproudhis L Pradat P Aynaud O Leocmach Y Soubeyrand B Dachez R Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study Int J Cancer 2011 129 2 433 9 10.1002/ijc.25671 20839262 · DOI
  18. [19]Lacau St Guily J Jacquard AC Pretet JL Haesebaert J Beby-Defaux A Clavel C Agius G Birembaut P Okais C Leocmach Y Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France–The EDiTH VI study J Clin Virol 2011 51 2 100 4 10.1016/j.jcv.2011.03.003 21527208 · DOI
  19. [22]Riethmuller D Pretet JL Denis F Aubin F Pradat P Clavel C Dachez R Gondry J Carcopino X Mougin C Expected impact of a quadrivalent HPV vaccine in France J Gynecol Obstet Biol Reprod 2009 38 5 389 95 10.1016/j.jgyn.2009.04.008 19481365 · DOI
  20. [24]Insinga RP Liaw KL Johnson LG Madeleine MM A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States Cancer Epidemiol Biomarkers Prev 2008 17 7 1611 22 10.1158/1055-9965.EPI-07-2922 18628412 PMC2587113 · DOI
  21. [25]Wentzensen N Schiffman M Dunn T Zuna RE Gold MA Allen RA Zhang R Sherman ME Wacholder S Walker J Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants Int J Cancer 2009 125 9 2151 8 10.1002/ijc.24528 19585494 PMC2755508 · DOI
  22. [26]Van de Velde N Boily MC Drolet M Franco EL Mayrand MH Kliewer EV Coutlee F Laprise JF Malagon T Brisson M Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis J Natl Cancer Inst 2012 104 22 1712 23 10.1093/jnci/djs395 23104323 · DOI · Paper page
  23. [29]Drolet M Laprise JF Boily MC Franco EL Brisson M Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine Int J Cancer 2014 134 9 2264 8 10.1002/ijc.28541 24174175 · DOI

Cited by

Sorted by citations

Authors
Riethmuller, D., Jacquard, A.-C., Lacau St Guily, J., Aubin, F., Carcopino, X., Pradat, P., Dahlab, A., & Prétet, J.-L.
Affiliations
  • Hôpital Saint-Jacques (FR)
  • Sanofi (France) (FR)
  • Centre National de la Recherche Scientifique (FR)
  • Hôpital de la Croix-Rousse (FR)
  • Centre Hospitalier Universitaire de Besançon (FR)
Corresponding author
Jacquard, Anne-Carole
ORCID
Venue
BMC Public Health
Publisher
Springer Science and Business Media LLC
Published
2015-05-02
Volume
15
Issue
1
Pages
453-453
ISSN
1471-2458 (ISSN-L)
DOI
10.1186/s12889-015-1779-1
PMC
PMC4433025
OpenAlex
W1995688817
Cited by
61
References
0
Citations by year
2026: 1 · 2025: 4 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 7 · 2019: 8 · 2018: 9 · 2017: 11 · 2016: 9 · 2015: 4
FWCI
8.63
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Public Health (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
Funders
  • Sanofi
  • Sanofi Pasteur
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Surgery › Genital Health and Disease
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
nonavalent HPV vaccine, HPV-related diseases, vaccine impact, cervical cancer, low-grade squamous intraepithelial lesion, genital warts, anal cancer, oropharyngeal cancer, HPV genotypes, quadrivalent vaccine, France
MeSH terms
Anus Neoplasms, Uterine Cervical Neoplasms, Female, France, Genotype, Humans, Male, Oropharyngeal Neoplasms, Retrospective Studies, Prevalence, Papillomavirus Infections, Alphapapillomavirus, Papillomavirus Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review